VIVOS INC 10-K — AI Bull & Bear Analysis

The 2025 10-K paints a picture of a high-risk, high-reward venture where technical success is currently decoupled from financial stability. Vivos has successfully proven the clinical utility of its radionuclide platform in the veterinary market, but it has yet to translate this into a sustainable business model. The gap between the 1,200% growth in therapies and the nominal revenue of $68,379 underscores a commercialization phase that is still in its infancy and currently operating at a loss. For investors, the central tension lies in the timing of the FDA's IDE decision versus the company's cash runway. A successful IDE approval in early 2026 would likely act as a massive catalyst, potentially easing the path for the necessary $9 million in capital raises. However, any further regulatory delays or failures to operationalize the new manufacturing sites could lead to a liquidity crisis. The company is essentially racing to achieve regulatory and operational milestones before its capital reserves are exhausted.